Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia

Cellectar reports 87.5% response rate in tough-to-treat WM, but approval remains years away.

What the company is saying

Cellectar Biosciences is highlighting strong efficacy and safety results from a 24-patient subgroup in its Phase 2b CLOVER WaM trial for relapsed or refractory Waldenström macroglobulinemia treated immediately after BTKi therapy. The company emphasizes that 75% of these patients were BTKi refractory and over 54% had received multiple BTKi regimens, underlining the high-risk population. Key efficacy metrics are presented: overall response rate of 87.5%, major response rate of 79.2%, and a clinical benefit rate of 100%, with median duration of response at 16.0 months and treatment-free survival of 19.1 months. Safety is framed as favorable, with treatment-emergent adverse events in less than 10% of patients and only cytopenias at Grade 3 or higher. The narrative stresses the potential of iopofosine I 131 as a new treatment option, referencing Breakthrough Therapy Designation and multiple orphan and fast track designations from the FDA and PRIME from the EMA. The company signals confidence by stating plans to begin a confirmatory Phase 3 trial in early 2027 and intent to file for accelerated FDA approval in the first half of 2027. Jarrod Longcor, chief operating officer, is quoted to reinforce the unmet need and the drug’s potential to address refractory disease.

What the data suggests

The disclosed data show that in a heavily pretreated, high-risk WM subgroup, iopofosine I 131 achieved an overall response rate of 87.5% and a major response rate of 79.2%. All patients derived clinical benefit, with a median duration of response of 16.0 months and treatment-free survival of 19.1 months. The subgroup included 75% BTKi-refractory patients and over 54% who had received multiple BTKi therapies, with 17% TP53 mutations and 29% MYD88 wild type, both markers of poor prognosis. Safety appears manageable, with less than 10% experiencing treatment-emergent adverse events and only cytopenias at Grade 3 or higher. The dataset meets regulatory expectations for surrogate endpoints and 12-month follow-up. However, these results are from a small, selected subgroup and are not yet validated in a randomized Phase 3 setting. No financial data, cash runway, or operational metrics are disclosed, and no enrollment or start date for the Phase 3 trial is provided. The evidence is strong for this subgroup but does not yet translate to regulatory approval or commercial viability.

Analysis

The announcement presents robust and specific clinical efficacy and safety data from a Phase 2b subgroup, with high response rates and favorable tolerability, which are well-supported by numerical evidence. However, the narrative is forward-leaning, emphasizing future milestones such as the initiation of a Phase 3 trial and a planned New Drug Application submission in 2027—both of which are at least 18 months away and contingent on further development. The tone is optimistic, referencing multiple regulatory designations and the potential for iopofosine I 131 to become a new treatment option, but these are not yet realized outcomes. No financial or capital outlay data are disclosed, and while the pipeline is highlighted, supporting data for other programs are minimal or absent. The gap between the company's positive narrative and the actual, realized progress is moderate: the clinical results are promising but limited to a small subgroup, and all commercial or regulatory benefits remain long-term and unproven.

Risk flags

• ●The clinical data, while strong, are limited to a small subgroup (n=24) and may not generalize to the broader WM population; results from the upcoming Phase 3 trial could differ materially.
• ●Regulatory approval is not guaranteed; the company is relying on surrogate endpoints and accelerated approval pathways, which may face additional scrutiny or require confirmatory evidence.
• ●No financial data, cash position, or funding plan for the Phase 3 trial is disclosed, raising questions about the company’s ability to execute its development and regulatory strategy through 2027.
• ●The timeline to commercial impact is long, with first patient dosing in Phase 3 and NDA submission both projected for 2027, exposing the company to clinical, regulatory, and funding risks over the next 18–24 months.

Bottom line

Cellectar’s subgroup data for iopofosine I 131 in relapsed or refractory WM are clinically impressive, with an 87.5% response rate and manageable safety profile in a high-risk, heavily pretreated population. The company is positioning these results as a springboard for a Phase 3 trial and an accelerated approval filing, but both milestones are at least several quarters away. The absence of financial disclosure leaves investors unable to assess whether the company can fund its planned development through to regulatory submission. The evidence supports optimism for the drug’s efficacy in this setting, but the small sample size and long execution timeline temper near-term expectations. Investors should watch for concrete updates on Phase 3 trial initiation, enrollment progress, and any financial or partnership developments. The most important takeaway is that while the clinical signal is strong, regulatory and commercial outcomes remain unproven and distant.

Announcement summary

(NASDAQ:CLRB) Cellectar Biosciences, Inc. announced efficacy results from a subgroup of 24 patients treated with iopofosine I 131 immediately after Bruton Tyrosine Kinase inhibitor (BTKi) therapy in the Phase 2b CLOVER WaM clinical trial for relapsed or refractory Waldenström macroglobulinemia (WM). The data were presented at the International Workshop for Waldenström Macroglobulinemia (IWWM) held October 14-16, 2026. In this subgroup, 75% were BTKi refractory and more than 54% had received multiple BTKi therapies. Patients had a median of three prior lines of therapy (range 2-7), with 17% being TP53 mutated and 29% being MYD88 wild type. The overall response rate (ORR) was 87.5%, the major response rate (MRR) was 79.2%, and the clinical benefit rate (CBR) was 100%. The median duration of response (DoR) was 16.0 months, and treatment free survival (TFS) was 19.1 months. Treatment emergent adverse events (TEAE) occurred in less than 10% of patients, with the only Grade 3 or higher TEAE being cytopenias. Cellectar is advancing plans to dose the first patients in a confirmatory Phase 3 randomized clinical trial in a post-first line, post-BTKi population, with progression-free survival (PFS) as the primary endpoint. The company is preparing to submit a New Drug Application for accelerated approval with the U.S. Food and Drug Administration (FDA) in the first half of 2027, supported by the CLOVER WaM dataset. The CLOVER WaM dataset includes use of surrogate endpoints (MRR supported by DoR), demonstration of durable responses in a high unmet need population, and completion of at least 12-month follow-up across all patients. Iopofosine I 131 has received Breakthrough Therapy Designation, six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations from the FDA, and PRIME designation from the EMA. The company’s pipeline also includes CLR 121125 (CLR 125), an iodine-125 Auger-emitting program for solid tumors, currently in Phase 1b for triple negative breast cancer (TNBC), and CLR 121225 (CLR 225), an actinium-225 based program targeting solid tumors such as pancreatic cancer. CLR 125 has shown strong preclinical data and has been well tolerated in vivo. Cellectar is also developing proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

Disagree with this article?